Jessica W. Templer

Dr. Jessica W. Templer

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2023 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
EAEdward K Avila
Edward K Avila
STSteven Tobochnik
Steven Tobochnik
SISara K Inati
Sara K Inati
JKJohan A. F. A.F. Koekkoek
Johan A. F. A.F. Koekkoek
GMGuy M McKhann
Guy M McKhann
PWPatrick Y Wen
Patrick Y Wen
Tumor-related epilepsy (TRE) is a frequent and major consequence of brain tumors. Management of TRE is required throughout the course of disease and a deep understanding of diagnosis and treatment is key to improving quality of life. Gross total resection is favored from both an oncologic and epilepsy perspective. Shared mechanisms of tumor growth and epilepsy exist, and emerging data will provide better targeted therapy options. Initial treatment with antiseizure medications (ASM) in conjunction with surgery and/or chemoradiotherapy is typical. The first choice of ASM is critical to optimize seizure control and tolerability considering the effects of the tumor itself. These agents carry a potential for drug–drug interactions and therefore knowledge of mechanisms of action and interactions is needed. A review of adverse effects is necessary to guide ASM adjustments and decision-making. This review highlights the essential aspects of diagnosis and treatment of TRE with ASMs, surgery, chemotherapy, and radiotherapy while indicating areas of uncertainty. Future studies should consider the use of a standardized method of seizure tracking and incorporating seizure outcomes as a primary endpoint of tumor treatment trials.

15 June 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MDMichael R. Drumm
Michael R. Drumm
WWWenxia Wang
Wenxia Wang
TSThomas Kieran Sears
Thomas Kieran Sears
KBKirsten Bell-Burdett
Kirsten Bell-Burdett
RJRodrigo Javier
Rodrigo Javier
CHCraig Horbinski
Craig Horbinski
Seizures are a frequent complication of adult-type diffuse gliomas, and are often difficult to control with medications. Gliomas with mutations in isocitrate dehydrogenase 1 or 2 (IDHmut) are more likely than IDH–wild type (IDHwt) gliomas to cause seizures as part of their initial clinical presentation. However, whether IDHmut is also associated with seizures during the remaining disease course, and whether IDHmut inhibitors can reduce seizure risk, are unclear. Clinical multivariable analyses showed that preoperative seizures, glioma location, extent of resection, and glioma molecular subtype (including IDHmut status) all contributed to postoperative seizure risk in adult-type diffuse glioma patients, and that postoperative seizures were often associated with tumor recurrence. Experimentally, the metabolic product of IDHmut, d-2-hydroxyglutarate, rapidly synchronized neuronal spike firing in a seizure-like manner, but only when non-neoplastic glial cells were present. In vitro and in vivo models recapitulated IDHmut glioma–associated seizures, and IDHmut inhibitors currently being evaluated in glioma clinical trials inhibited seizures in those models, independent of their effects on glioma growth. These data show that postoperative seizure risk in adult-type diffuse gliomas varies in large part by molecular subtype, and that IDHmut inhibitors could play a key role in mitigating such risk in IDHmut glioma patients.

9 January 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
STShashwat Tripathi
Shashwat Tripathi
CNCody L. Nathan
Cody L. Nathan
MTMatthew C. Tate
Matthew C. Tate
CHCraig M. Horbinski
Craig M. Horbinski
JTJessica W. Templer
Jessica W. Templer
Amy B. HeimbergerAmy B. Heimberger
Amy B. Heimberger
Epilepsy has a profound impact on quality of life. Despite the development of new antiseizure medications (ASMs), approximately one-third of affected patients have drug-refractory epilepsy and are nonresponsive to medical treatment. Nearly all currently approved ASMs target neuronal activity through ion channel modulation. Recent human and animal model studies have implicated new immunotherapeutic and metabolomic approaches that may benefit patients with epilepsy. In this Review, we detail the proinflammatory immune landscape of epilepsy and contrast this with the immunosuppressive microenvironment in patients with glioma-related epilepsy. In the tumor setting, excessive neuronal activity facilitates immunosuppression, thereby contributing to subsequent glioma progression. Metabolic modulation of the IDH1-mutant pathway provides a dual pathway for reversing immune suppression and dampening seizure activity. Elucidating the relationship between neurons and immunoreactivity is an area for the prioritization and development of the next era of ASMs.

4 January 2021 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
NBNupur Brahmbhatt
Nupur Brahmbhatt
RSRoger Stupp
Roger Stupp
OBOmar Bushara
Omar Bushara
EBElizabeth Bachman
Elizabeth Bachman
SSStephan U. Schuele
Stephan U. Schuele
JTJessica W. Templer
Jessica W. Templer

18 April 2025 in Neuro-Oncology
Verified
Journal Article
Closed access
BKBobak Khalili
Bobak Khalili
KDKaran Dixit
Karan Dixit
DKDavid Olayinka Kamson
David Olayinka Kamson
CHCraig Horbinski
Craig Horbinski
DPDelilah J Przybyla
Delilah J Przybyla
JTJessica W. Templer
Jessica W. Templer
Gliomas are the most common primary malignant brain tumors. Their electrobiologic properties drive disease development, and in select tumors, aberrant neurosignaling is situated at the crux of gliomagenesis and glioma-related epilepsy. Tumor microtubes and the neuronal-glioma synapse are defined components of the glioma circuitry. The nidus of cortical hyperexcitability—the peri-glioma—undergoes severe alterations during disease progression and is influenced by genetic mutations, anomalous synaptic remodeling, inflammatory changes, and an imbalance in neurotransmitters. Such pathologic mechanisms have been exploited for anticancer and anti-seizure value wherein a subset remains to be explored. In this Review, we discuss the hyperexcitable conditions within the glioma microenvironment and candidate therapies for seizure and tumor control.

19 October 2024 in Neuro-Oncology Practice
Verified
Journal Article
Closed access
TWTobias Walbert
Tobias Walbert
EAEdward K Avila
Edward K Avila
FBFlorien W Boele
Florien W Boele
CHCaroline Hertler
Caroline Hertler
CLChristine Lu-Emerson
Christine Lu-Emerson
JKJohan A. F. A.F. Koekkoek
Johan A. F. A.F. Koekkoek
According to the 2021 World Health Organization classification of CNS tumors, gliomas harboring a mutation in isocitrate dehydrogenase (mIDH) are considered a distinct disease entity, typically presenting in adult patients before the age of 50 years. Given their multiyear survival, patients with mIDH glioma are affected by tumor and treatment-related symptoms that can have a large impact on the daily life of both patients and their caregivers for an extended period of time. Selective oral inhibitors of mIDH enzymes have recently joined existing anticancer treatments, including resection, radiotherapy, and chemotherapy, as an additional targeted treatment modality. With new treatments that improve progression-free and possibly overall survival, preventing and addressing daily symptoms becomes even more clinically relevant. In this review we discuss the management of the most prevalent symptoms, including tumor-related epilepsy, cognitive dysfunction, mood disorders, and fatigue, in patients with mIDH glioma, and issues regarding patient’s health-related quality of life and caregiver needs in the era of mIDH inhibitors. We provide recommendations for practicing healthcare professionals caring for patients who are eligible for treatment with mIDH inhibitors.